Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Capricor Therapeutics, Inc.NASDAQ: CAPR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $534.67K rose 31.9% year over year, behind the +66925.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +52.5% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +31.9% toward the trailing-twelve-month pace of +66925.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.89M USD
- Year-over-year change
- +32.5%
- 4-year CAGR
- +66.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.89M | +32.5% |
| FY2024 | 2024-12-31 | 1.43M | +33.3% |
| FY2023 | 2023-12-31 | 1.07M | +100.5% |
| FY2022 | 2022-12-31 | 533.13K | +117.0% |
| FY2021 | 2021-12-31 | 245.7K | — |
Depreciation & Amortization vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's LTM Mar 2026 depreciation & amortization of $1B is the highest of the 10 companies compared; the peer median is $3.2M.
- Its year-over-year change of +66925.2% is the highest of 10, against a peer median of +4.0%.
- Over three fiscal years its annual growth of +52.5% compares with a peer median of +0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1B | +66925.2% | +52.5% | — | |
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Mar 2026 | $45.14M | +15.9% | +2.1% | 2.1% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $8.99M | +4.0% | -4.3% | 12.5% | |
| LTM Mar 2026 | $3.2M | -40.7% | +41.5% | — | |
| LTM Jun 2026 | $2.15M | +13.8% | +6.8% | — | |
| LTM Sep 2026 | $1.76M | -24.1% | +61.5% | — | |
| LTM Mar 2026 | $1.62M | -35.9% | -12.1% | — | |
| LTM Mar 2026 | $284K | -92.5% | -39.2% | 4.9% | |
| Peer median (excluding CAPR) | $3.2M | +4.0% | +0.9% | 4.9% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 244.9K | 2.55M | 25.18M | 22.27M | 0 |
| Cost of Revenue | 0 | 21.82M | 36.45M | 49.97M | 0 |
| Gross Profit | 244.9K | (19.27M) | (11.27M) | (27.7M) | 0 |
| Gross Margin | 100.0% | -755.1% | -44.8% | -124.4% | — |
| Research & Development | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M |
| Selling, General & Admin | 7.61M | 10.43M | 12.81M | 14.87M | 22.75M |
| Operating Expenses | 21.18M | 10.43M | 12.81M | 14.87M | 108.14M |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| EBITDA | (19.78M) | (28.49M) | (21.22M) | (39.04M) | (100.11M) |
| EBITDA Margin | -8075.5% | -1116.5% | -84.3% | -175.3% | — |
| Operating Income | (20.94M) | (29.7M) | (24.08M) | (42.56M) | (108.14M) |
| Operating Margin | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Interest Income | 0 | 521.53K | 1.73M | 2.2M | 6.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.05M |
| Other Income / Expenses | 915.92K | 677.85K | 1.79M | 2.1M | 3.1M |
| Income Before Tax | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Pre-Tax Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Net Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (Basic) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| EPS (Diluted) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| Weighted Avg Shares | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
| Weighted Avg Shares (Diluted) | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.